Starboard not short Celgene shares, CNBC’s Faber reports
Starboard Value does not have a short position in shares of Celgene (CELG), CNBC’s David Faber reports, citing sources. Starboard has said Bristol-Myers Squibb’s (BMY) planned takeover of Celgene is not in the best interests of its shareholders.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.